

Infectious Disease Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (Immunodiagnosics, NGS, PCR, ISH, INAAT), Disease (Hepatitis, HIV, HAI, HPV, Syphilis, TB, Flu) - Global Forecast to 2028

Market Report | 2024-01-09 | 303 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The infectious disease diagnostics market is valued at an estimated USD 21.4 billion in 2023 and is projected to reach USD 31.5 billion by 2028 at a CAGR of 8.0% during the forecast period. The rising focus on decentralized diagnostics and the growing demand for CLIA-waived PoC tests have driven the use of PoC technologies. The trend towards decentralized PoC testing in the infectious disease diagnostics market is further fueled by the need for more efficient healthcare delivery. Centralized laboratories often face challenges such as longer turnaround times and logistical complexities, particularly in remote or underserved areas. The decentralization of testing to point-of-care settings empowers healthcare professionals with the ability to conduct diagnostics at the patient's side, reducing the time between sample collection and result delivery. This paradigm shift not only supports timely patient care but also aids in the prompt identification and containment of infectious diseases, ultimately contributing to improved public health outcomes.

"PoC testing segment accounted for the highest growth rate in the infectious disease diagnostics market, by type of testing, during the forecast period."

The infectious disease diagnostics market is bifurcated into laboratory testing and PoC testing. The PoC testing segment in the infectious disease diagnostics market is experiencing substantial growth. The growth of the PoC segment is being fueled by the investments made by numerous companies, including their focus on new developments such as product launches and acquisitions. One of the main advantages of using PoC testing in hospitals or clinics over laboratory tests is that they have a faster turnaround time for testing than laboratory tests. Additionally, PoC testing requires lower sample volumes than traditional laboratory tests. Thus, the need to closely monitor patient conditions and advantages such as a faster diagnosis rate are the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

major factors driving the demand for PoC tests.

"DNA sequencing & next-generation sequencing segment accounted for the highest growth rate in the infectious disease diagnostics market, by technology, during the forecast period."

The infectious disease diagnostics market is bifurcated into immunodiagnostics, clinical microbiology, polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies based on technology. DNA sequencing & next-generation sequencing segment is expected to account for the highest CAGR during the forecast period. DNA sequencing is an easy platform that can be set up directly in the clinic for quick results. The ability to sequence DNA has opened opportunities for applications in various research fields, such as personalized medicine, cancer research, drug discovery, and agricultural and animal sciences. Factors such as advancements in sequencing technologies, a wide range of applications of sequencing technologies, and the growing demand for personalized medicine are factors expected to support market growth in the coming years.

"Asia Pacific: The fastest-growing region infectious disease diagnostics market"

The global infectious disease diagnostics market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to witness the highest growth during the forecast period. Emerging countries in this region are witnessing growth in their GDPs and a significant rise in disposable income levels. This has led to increased healthcare spending by a larger population base. Other factors such as the increasing incidence & prevalence of infectious diseases, healthcare infrastructure modernization, and the rising penetration of cutting-edge technologies (especially in rural areas) in Asia Pacific countries are also expected to provide significant growth opportunities for infectious disease diagnostics companies in this region.

The break-up of the profile of primary participants in the infectious disease diagnostics market:

-□By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%

-□By Designation: C-level - 27%, D-level - 18%, and Others - 55%

-□By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in this market are Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Siemens Healthineers AG (Germany), Danaher (US), Hologic, Inc. (US), Becton, Dickinson and Company (US), Revvity (US), QIAGEN (Netherlands), Seegene Inc. (South Korea), Grifols, S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), QuidelOrtho Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech (Ireland), Chembio Diagnostics, Inc. (US), Co-Diagnostics, Inc. (US), ELITech Group (France), Epitope Diagnostics, Inc. (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc. (US), Vela Diagnostics (Singapore), and Uniogen Oy (Finland).

Research Coverage:

This research report categorizes the infectious disease diagnostics market by product & service (reagents, kits, and consumables, instruments, and software & services), by type of testing (laboratory testing, PoC testing), by technology (immunodiagnostics, polymerase chain reaction, clinical microbiology, isothermal nucleic acid amplification technology, dna sequencing & next-generation sequencing, dna microarray, and other technologies), by disease type (hepatitis, HIV, hospital-acquired infections, mosquito-borne diseases, HPV, Chlamydia trachomatis, Neisseria gonorrhea, tuberculosis, influenza, syphilis, and other infectious diseases), by sample type (blood, serum, and plasma, urine, and other sample types), by end user (diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the infectious disease diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches and recent developments associated with the infectious disease diagnostics market. Competitive analysis of upcoming startups in the infectious disease diagnostics market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

numbers for the overall infectious disease diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (Rising prevalence of infectious diseases, Rising focus on R&D and funding in infectious disease diagnostic products, Growing awareness for early disease diagnosis in emerging economies, Adoption of new and advanced technologies for infectious disease diagnosis, Shift in focus from centralized laboratories to decentralized PoC testing centers), opportunities (Increased growth opportunities in emerging economies), restraints (Unfavorable reimbursement scenario), and challenges (Changing regulatory landscape, Operational barriers and shortage of skilled laboratory technicians) influencing the growth of the infectious disease diagnostics market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the infectious disease diagnostics market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the infectious disease diagnostics market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the infectious disease diagnostics market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMerieux (France), Siemens Healthineers AG (Germany), Danaher (US), and Thermo Fisher Scientific Inc. (US), among others in the infectious disease diagnostics market strategies.

Table of Contents:

1□INTRODUCTION□	33
1.1□STUDY OBJECTIVES□	33
1.2□MARKET DEFINITION□	33
1.3□INCLUSIONS & EXCLUSIONS□	34
1.4□STUDY SCOPE□	35
1.4.1□MARKETS COVERED□	35
1.4.2□REGIONS COVERED□	36
1.4.3□YEARS CONSIDERED□	36
1.4.4□CURRENCY CONSIDERED□	37
1.5□RESEARCH LIMITATIONS□	37
1.6□STAKEHOLDERS□	37
1.7□SUMMARY OF CHANGES□	38
2□RESEARCH METHODOLOGY□	39
2.1□RESEARCH DATA□	39
2.2□RESEARCH APPROACH□	39
FIGURE 1□RESEARCH DESIGN METHODOLOGY□	39
2.2.1□SECONDARY DATA□	40
2.2.1.1□Key data from secondary sources□	41
2.2.2□PRIMARY DATA□	42
FIGURE 2□PRIMARY SOURCES□	42
2.2.2.1□Key data from primary sources□	43
2.2.3□KEY INDUSTRY INSIGHTS□	44
2.2.3.1□Breakdown of primary interviews□	44
FIGURE 3□BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS□	44
FIGURE 4□BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION□	45

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.3	MARKET SIZE ESTIMATION	45
2.3.1	BOTTOM-UP APPROACH	46
2.3.2	COMPANY REVENUE ESTIMATION APPROACH	46
FIGURE 5	COMPANY REVENUE ESTIMATION APPROACH: INFECTIOUS DISEASE DIAGNOSTICS MARKET	46
2.3.3	PRESENTATIONS OF COMPANIES AND PRIMARY INTERVIEWS	46
2.3.4	GROWTH FORECAST	47
2.3.5	CAGR PROJECTIONS	47
FIGURE 6	CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS	47
2.3.6	TOP-DOWN APPROACH	47
FIGURE 7	TOP-DOWN APPROACH	48
?		
2.4	MARKET BREAKDOWN AND DATA TRIANGULATION	49
FIGURE 8	DATA TRIANGULATION METHODOLOGY	49
2.5	MARKET SHARE ASSESSMENT	50
2.6	STUDY ASSUMPTIONS	50
2.6.1	GROWTH RATE ASSUMPTIONS	50
2.7	RISK ASSESSMENT	51
TABLE 1	RISK ASSESSMENT: INFECTIOUS DISEASE DIAGNOSTICS MARKET	51
2.8	IMPACT OF RECESSION ON INFECTIOUS DISEASE DIAGNOSTICS MARKET	51
3	EXECUTIVE SUMMARY	53
FIGURE 9	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)	53
FIGURE 10	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023 VS. 2028 (USD MILLION)	54
FIGURE 11	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)	55
FIGURE 12	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)	56
FIGURE 13	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD MILLION)	57
FIGURE 14	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	58
FIGURE 15	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)	58
4	PREMIUM INSIGHTS	60
4.1	INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW	60
FIGURE 16	GROWING PREVALENCE OF INFECTIOUS DISEASE AND INCREASING INVESTMENT IN R&D TO DRIVE MARKET	60
4.2	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)	61
FIGURE 17	REAGENTS, KITS, AND CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD	61
4.3	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023 VS. 2028 (USD MILLION)	61
FIGURE 18	LABORATORY TESTING TO DOMINATE MARKET DURING STUDY PERIOD	61
4.4	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)	62
FIGURE 19	BLOOD, SERUM, AND PLASMA TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD	62
4.5	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)	62
FIGURE 20	IMMUNODIAGNOSTICS TO DOMINATE MARKET DURING FORECAST PERIOD	62
4.6	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD MILLION)	63
FIGURE 21	HEPATITIS TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD	63
4.7	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	63
FIGURE 22	DIAGNOSTIC LABORATORIES TO DOMINATE MARKET DURING STUDY PERIOD	63
4.8	REGIONAL GROWTH OPPORTUNITIES	64
FIGURE 23	ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD	64
5	MARKET OVERVIEW	65
5.1	INTRODUCTION	65
5.2	MARKET DYNAMICS	65

FIGURE 24 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: INFECTIOUS DISEASE DIAGNOSTICS MARKET 65

5.2.1 DRIVERS 66

5.2.1.1 Rising prevalence of infectious diseases 66

5.2.1.2 Rising focus on R&D and funding for infectious disease diagnostic products 67

5.2.1.3 Growing awareness for early disease diagnosis in emerging economies 68

5.2.1.4 Adoption of new and advanced technologies for infectious disease diagnosis 68

5.2.1.5 Shift in focus from centralized laboratories to decentralized PoC testing centers 69

5.2.2 RESTRAINTS 70

5.2.2.1 Unfavorable reimbursement scenario 70

5.2.3 OPPORTUNITIES 70

5.2.3.1 Increased growth opportunities in emerging economies 70

5.2.4 CHALLENGES 71

5.2.4.1 Changing regulatory landscape 71

5.2.4.2 Operational barriers and shortage of skilled laboratory technicians 71

5.3 PRICING ANALYSIS 71

TABLE 2 INDICATIVE PRICING FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS 71

TABLE 3 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION 72

5.4 PATENT ANALYSIS 73

FIGURE 25 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013-DECEMBER 2022) 73

TABLE 4 LIST OF MAJOR PATENTS, JANUARY 2021-DECEMBER 2022 74

5.5 VALUE CHAIN ANALYSIS 75

FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 75

5.6 SUPPLY CHAIN ANALYSIS 76

FIGURE 27 SUPPLY CHAIN ANALYSIS: INFECTIOUS DISEASE DIAGNOSTICS MARKET 77

5.7 ECOSYSTEM MARKET MAP 77

FIGURE 28 ECOSYSTEM MARKET MAP: INFECTIOUS DISEASE DIAGNOSTICS MARKET 78

TABLE 5 ROLE IN ECOSYSTEM 78

5.8 PORTER'S FIVE FORCES ANALYSIS 79

TABLE 6 PORTER'S FIVE FORCES ANALYSIS 79

5.8.1 THREAT OF NEW ENTRANTS 79

5.8.2 THREAT OF SUBSTITUTES 79

5.8.3 BARGAINING POWER OF BUYERS 79

5.8.4 BARGAINING POWER OF SUPPLIERS 80

5.8.5 INTENSITY OF COMPETITIVE RIVALRY 80

5.9 REGULATORY LANDSCAPE 80

5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80

TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80

TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81

TABLE 9 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81

TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82

5.9.2 NORTH AMERICA 82

5.9.2.1 US 82

5.9.2.2 Canada 82

5.9.3 EUROPE 82

TABLE 11 EUROPE: CLASSIFICATION OF DEVICES 83

5.9.4 ASIA PACIFIC 83

5.9.4.1 China 83

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.9.4.2	Japan	83
TABLE 12	JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	84
5.9.4.3	India	84
5.9.5	LATIN AMERICA	84
5.9.5.1	Brazil	84
5.9.5.2	Mexico	85
5.9.6	MIDDLE EAST	85
5.9.6.1	Africa	85
5.10	TRADE ANALYSIS	85
TABLE 13	IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)	85
TABLE 14	EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)	86
5.11	TECHNOLOGY ANALYSIS	86
5.12	KEY CONFERENCES & EVENTS	87
TABLE 15	DETAILED LIST OF KEY CONFERENCES & EVENTS IN 2022-2023	87
5.13	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	89
FIGURE 29	REVENUE SHIFT IN INFECTIOUS DISEASE DIAGNOSTICS MARKET	89
5.14	KEY STAKEHOLDERS & BUYING CRITERIA	90
5.14.1	KEY STAKEHOLDERS IN BUYING PROCESS	90
FIGURE 30	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS	90
TABLE 16	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%)	90
5.14.2	BUYING CRITERIA	91
FIGURE 31	KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS	91
TABLE 17	KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS	91
5.15	CASE STUDY ANALYSIS	92
FIGURE 32	CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA	92
6	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE	93
6.1	INTRODUCTION	94
TABLE 18	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	94
TABLE 19	PRICES OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, 2022	94
6.2	REAGENTS, KITS, AND CONSUMABLES	95
6.2.1	RECURRENT PURCHASES OF REAGENTS, KITS, AND CONSUMABLES TO DRIVE MARKET	95
TABLE 20	INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY REGION, 2021-2028 (USD MILLION)	96
6.3	INSTRUMENTS	96
6.3.1	INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS WITH MINIMUM HUMAN INTERVENTION TO DRIVE MARKET	96
TABLE 21	KEY INSTRUMENTS AVAILABLE IN MARKET	97
TABLE 22	INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)	98
6.4	SOFTWARE & SERVICES	98
6.4.1	GROWING UPTAKE OF ADVANCED INSTRUMENTS AND INCREASING COMPETITIVENESS FOR VALUE-ADDED SERVICES TO DRIVE MARKET	98
TABLE 23	INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021-2028 (USD MILLION)	99
7	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING	100
7.1	INTRODUCTION	101
TABLE 24	INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2021-2028 (USD MILLION)	101
7.1.1	PRIMARY NOTES	101
FIGURE 33	KEY INDUSTRY INSIGHTS: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING	101

7.2 LABORATORY TESTING102

7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET102

TABLE 25 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY REGION, 2021-2028 (USD MILLION)103

7.3 POC TESTING103

7.3.1 FASTER TURNAROUND TIME AND MORE EFFICIENT TREATMENT OPTIONS TO DRIVE MARKET103

TABLE 26 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY REGION, 2021-2028 (USD MILLION)104

8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE105

8.1 INTRODUCTION106

TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)106

8.1.1 PRIMARY NOTES106

FIGURE 34 KEY INDUSTRY INSIGHTS: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE106

8.2 BLOOD, SERUM, AND PLASMA107

8.2.1 HIGHER VERSATILITY, GREATER CLINICAL EFFICACY, AND BETTER REIMBURSEMENT POLICIES TO DRIVE MARKET107

TABLE 28 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021-2028 (USD MILLION)108

8.3 URINE108

8.3.1 NON-INVASIVE NATURE OF URINE SAMPLES TO DRIVE MARKET108

TABLE 29 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE, BY REGION, 2021-2028 (USD MILLION)109

8.4 OTHER SAMPLE TYPES109

TABLE 30 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021-2028 (USD MILLION)109

9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE110

9.1 INTRODUCTION111

TABLE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)111

9.2 HEPATITIS111

TABLE 32 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2021-2028 (USD MILLION)112

TABLE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2021-2028 (MILLION TESTS)113

TABLE 34 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY METHOD, 2021-2028 (USD MILLION)113

TABLE 35 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2021-2028 (USD MILLION)113

9.2.1 HEPATITIS B114

9.2.1.1 Increasing global prevalence of hepatitis B to drive segment114

TABLE 36 HEPATITIS B MARKET, BY REGION, 2021-2028 (USD MILLION)114

9.2.2 HEPATITIS C114

9.2.2.1 Rising number of government initiatives for hepatitis C diagnosis to drive segment114

TABLE 37 HEPATITIS C MARKET, BY REGION, 2021-2028 (USD MILLION)115

9.2.3 OTHER HEPATITIS DISEASES115

TABLE 38 OTHER HEPATITIS DISEASES MARKET, BY REGION, 2021-2028 (USD MILLION)116

9.3 HIV116

9.3.1 GROWING PREVALENCE OF AIDS AND INCREASING AVAILABILITY OF HIV POC TESTING TO DRIVE MARKET116

TABLE 39 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2021-2028 (USD MILLION)117

TABLE 40 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2021-2028 (MILLION TESTS)117

9.4 HOSPITAL-ACQUIRED INFECTIONS117

9.4.1 RISING BURDEN OF INFECTIONS AND INCREASING ADOPTION OF ADVANCED DIAGNOSTIC TESTS TO DRIVE MARKET117

TABLE 41 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021-2028 (USD MILLION)118

TABLE 42 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021-2028 (MILLION TESTS)119

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.5 MOSQUITO-BORNE DISEASES 119

9.5.1 RISING INCIDENCE OF DENGUE AND MALARIA AND INCREASING NUMBER OF AWARENESS PROGRAMS TO DRIVE MARKET 119

TABLE 43 MAJOR PRODUCTS FOR DENGUE TESTING AVAILABLE IN MARKET 120

TABLE 44 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2021-2028 (USD MILLION) 121

9.6 HPV 121

9.6.1 TECHNOLOGICAL ADVANCEMENTS FOR PREVENTING HPV INFECTIONS TO DRIVE MARKET 121

TABLE 45 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2021-2028 (USD MILLION) 122

TABLE 46 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2021-2028 (MILLION TESTS) 122

9.7 CHLAMYDIA TRACHOMATIS 122

9.7.1 GROWING INCIDENCE OF CHLAMYDIA AND RISING AWARENESS AMONG PATIENTS TO DRIVE MARKET 122

TABLE 47 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2021-2028 (USD MILLION) 123

TABLE 48 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2021-2028 (MILLION TESTS) 123

9.8 NEISSERIA GONORRHEA 124

9.8.1 RISING INCIDENCE OF GONORRHEA AND GROWING FUNDING FOR R&D TO DRIVE MARKET 124

TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA, BY REGION, 2021-2028 (USD MILLION) 124

9.9 TUBERCULOSIS 124

9.9.1 INCREASING BURDEN OF TUBERCULOSIS IN UNDERDEVELOPED NATIONS TO DRIVE MARKET 124

TABLE 50 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2021-2028 (USD MILLION) 125

TABLE 51 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2021-2028 (MILLION TESTS) 125

TABLE 52 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY METHOD, 2021-2028 (USD MILLION) 126

9.10 INFLUENZA 126

9.10.1 RISING FOCUS ON FASTER DIAGNOSIS AND CONTROL TO DRIVE MARKET 126

TABLE 53 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2021-2028 (USD MILLION) 126

TABLE 54 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2021-2028 (MILLION TESTS) 127

TABLE 55 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY METHOD, 2021-2028 (USD MILLION) 127

9.11 SYPHILIS 127

9.11.1 GROWING ADOPTION OF NOVEL TECHNOLOGIES FOR IMPROVED SCREENING TO DRIVE MARKET 127

TABLE 56 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2021-2028 (USD MILLION) 128

9.12 OTHER INFECTIOUS DISEASES 128

TABLE 57 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION) 129

9.13 COVID-19 129

9.13.1 DECLINING CASES OF COVID-19 TO LIMIT MARKET 129

TABLE 58 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2021-2028 (USD MILLION) 130

10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY 131

10.1 INTRODUCTION 132

10.2 PRIMARY NOTES 132

FIGURE 35 KEY INDUSTRY INSIGHTS: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY 132

TABLE 59 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 133

10.3 IMMUNODIAGNOSTICS 133

10.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET 133

TABLE 60 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION) 134

10.4 CLINICAL MICROBIOLOGY 134

10.4.1 QUICKER TURNAROUND TIME FOR RESULTS WITH HIGHER SENSITIVITY AND RELIABILITY TO DRIVE MARKET 134

TABLE 61 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2021-2028 (USD MILLION) 135

10.5 POLYMERASE CHAIN REACTION 135

10.5.1 EASE OF USE, COST-EFFECTIVENESS, AND HIGH SPECIFICITY TO DRIVE MARKET 135

TABLE 62 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021-2028 (USD MILLION) 136

10.6 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 137

10.6.1 LOWER COST AND BETTER SUITABILITY FOR POINT-OF-CARE TESTING TO DRIVE MARKET 137

TABLE 63 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2021-2028 (USD MILLION) 137

10.7 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 138

10.7.1 ADVANCEMENTS IN SEQUENCING TECHNOLOGIES AND INCREASED FOCUS ON MOLECULAR TARGETED DRUGS TO DRIVE MARKET 138

TABLE 64 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2021-2028 (USD MILLION) 138

10.8 DNA MICROARRAY 139

10.8.1 HIGH INSTRUMENT COSTS AND NEED FOR EXPERT TECHNICIANS TO LIMIT MARKET 139

TABLE 65 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAY, BY REGION, 2021-2028 (USD MILLION) 139

10.9 OTHER TECHNOLOGIES 139

TABLE 66 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION) 140

11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER 141

11.1 INTRODUCTION 142

TABLE 67 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION) 142

11.2 DIAGNOSTIC LABORATORIES 142

11.2.1 DEVELOPMENT OF LOW-COST AND HIGHLY SPECIALIZED SCREENING TESTS TO DRIVE MARKET 142

TABLE 68 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2028 (USD MILLION) 143

11.3 HOSPITALS & CLINICS 143

11.3.1 INCREASING ADOPTION OF DIAGNOSTIC TOOLS AND BETTER REIMBURSEMENT FACILITIES TO DRIVE MARKET 143

TABLE 69 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021-2028 (USD MILLION) 144

11.4 ACADEMIC RESEARCH INSTITUTES 144

11.4.1 INCREASING FOCUS ON R&D FOR DEVELOPING INNOVATIVE TESTS TO DRIVE MARKET 144

TABLE 70 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION) 145

11.5 OTHER END USERS 145

TABLE 71 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION) 146

12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION 147

12.1 INTRODUCTION 148

TABLE 72 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2021-2028 (USD MILLION) 148

12.2 NORTH AMERICA 148

FIGURE 36 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT 149

TABLE 73 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 150

TABLE 74 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 150

TABLE 75 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 150

TABLE 76 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION) 151

TABLE 77 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION) 151

12.2.1 NORTH AMERICA: RECESSION IMPACT 152

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.2.2 US 152

12.2.2.1 Increasing prevalence of infectious diseases to drive market 152

TABLE 78 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 152

TABLE 79 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 153

TABLE 80 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION) 153

TABLE 81 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION) 154

12.2.3 CANADA 154

12.2.3.1 Focus on affordable tests and use of personalized medicine to drive market 154

TABLE 82 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 154

TABLE 83 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 155

TABLE 84 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION) 155

TABLE 85 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION) 156

12.3 EUROPE 156

TABLE 86 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 157

TABLE 87 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 157

TABLE 88 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 158

TABLE 89 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION) 158

TABLE 90 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION) 159

12.3.1 EUROPE: RECESSION IMPACT 159

12.3.2 GERMANY 159

12.3.2.1 Increasing healthcare expenditure and rising per capita disposable income to drive market 159

TABLE 91 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 160

TABLE 92 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 160

TABLE 93 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION) 161

TABLE 94 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION) 161

12.3.3 UK 162

12.3.3.1 Growing number of accredited diagnostic and hospital laboratories to drive market 162

TABLE 95 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 162

TABLE 96 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 163

TABLE 97 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION) 163

TABLE 98 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION) 164

12.3.4 FRANCE 164

12.3.4.1 Rising R&D expenditure and increasing demand for early diagnosis to drive market 164

TABLE 99 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 164

TABLE 100 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 165

TABLE 101 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION) 165

TABLE 102 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION) 166

12.3.5 ITALY 166

12.3.5.1 Increased adoption of advanced diagnostic technologies and growing government healthcare investment to drive market 166

TABLE 103 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 166

TABLE 104 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 167

TABLE 105 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION) 167

TABLE 106 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION) 168

12.3.6 SPAIN 168

12.3.6.1 Rising geriatric population and improving healthcare infrastructure to drive market 168

TABLE 107 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 169

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 108	SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	169
TABLE 109	SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)	170
TABLE 110	SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	170
12.3.7	REST OF EUROPE	171
TABLE 111	GDP EXPENDITURE ON HEALTHCARE, BY COUNTRY (%)	171
TABLE 112	REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	171
TABLE 113	REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	172
TABLE 114	REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)	172
TABLE 115	REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	173
12.4	ASIA PACIFIC	173
FIGURE 37	ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT	174
TABLE 116	ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	174
TABLE 117	ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	175
TABLE 118	ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	175
TABLE 119	ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)	176
TABLE 120	ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	176
12.4.1	ASIA PACIFIC: RECESSION IMPACT	177
12.4.2	CHINA	177
12.4.2.1	Increased public access to modern healthcare and favorable government policies to drive market	177
TABLE 121	CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	177
TABLE 122	CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	178
TABLE 123	CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)	178
TABLE 124	CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	179
12.4.3	JAPAN	179
12.4.3.1	Presence of well-developed healthcare system and universal reimbursement policies to drive market	179
TABLE 125	JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	180
TABLE 126	JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	180
TABLE 127	JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)	181
TABLE 128	JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	181
12.4.4	INDIA	182
12.4.4.1	Increasing private and public investments in healthcare system to drive market	182
TABLE 129	INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	182
TABLE 130	INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	183
TABLE 131	INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)	183
TABLE 132	INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	184
12.4.5	REST OF ASIA PACIFIC	184
TABLE 133	REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	184
TABLE 134	REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	185
TABLE 135	REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)	185
TABLE 136	REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	186
12.5	LATIN AMERICA	186
12.5.1	RIISING PREVALENCE OF INFECTIOUS DISEASES AND INCREASING HEALTHCARE EXPENDITURE TO DRIVE MARKET	186
TABLE 137	LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	187
TABLE 138	LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	187
TABLE 139	LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)	188
TABLE 140	LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	188

12.5.2	LATIN AMERICA: RECESSION IMPACT	189
12.6	MIDDLE EAST & AFRICA	189
TABLE 141	MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	189
TABLE 142	MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	190
TABLE 143	MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	190
TABLE 144	MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)	191
TABLE 145	MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	191
12.6.1	MIDDLE EAST & AFRICA: RECESSION IMPACT	192
12.6.2	GCC COUNTRIES	192
12.6.2.1	Rising focus on advanced health infrastructure to drive market	192
TABLE 146	GCC COUNTRIES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	193
TABLE 147	GCC COUNTRIES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	193
TABLE 148	GCC COUNTRIES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)	194
TABLE 149	GCC COUNTRIES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	194
12.6.3	REST OF MIDDLE EAST & AFRICA	195
TABLE 150	REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	195
TABLE 151	REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	195
TABLE 152	REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)	196
TABLE 153	REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	196
13	COMPETITIVE LANDSCAPE	197
13.1	OVERVIEW	197
13.2	KEY STRATEGIES/RIGHT TO WIN	197
13.2.1	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS	198
TABLE 154	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET	198
13.3	REVENUE SHARE ANALYSIS	200
FIGURE 38	REVENUE SHARE ANALYSIS OF TOP PLAYERS	200
13.4	MARKET SHARE ANALYSIS	201
FIGURE 39	INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022)	201
TABLE 155	DEGREE OF COMPETITION: INFECTIOUS DISEASE DIAGNOSTICS MARKET	201
13.5	COMPANY EVALUATION MATRIX	202
13.5.1	STARS	202
13.5.2	EMERGING LEADERS	203
13.5.3	PERVASIVE PLAYERS	203
13.5.4	PARTICIPANTS	203
FIGURE 40	COMPANY EVALUATION MATRIX, 2022	203
13.5.5	COMPANY FOOTPRINT	204
FIGURE 41	PRODUCT AND REGIONAL FOOTPRINT OF KEY PLAYERS	204
TABLE 156	COMPANY FOOTPRINT	204
TABLE 157	PRODUCT & SERVICE FOOTPRINT	205
TABLE 158	REGIONAL FOOTPRINT	205
13.6	START-UP/SME EVALUATION MATRIX	206
13.6.1	PROGRESSIVE COMPANIES	206

13.6.2	RESPONSIVE COMPANIES	206
13.6.3	DYNAMIC COMPANIES	206
13.6.4	STARTING BLOCKS	206
FIGURE 42	START-UP/SME EVALUATION MATRIX, 2022	207
13.6.5	COMPETITIVE BENCHMARKING	207
TABLE 159	DETAILED LIST OF KEY START-UPS/SMES	207
13.7	COMPETITIVE SCENARIOS AND TRENDS	208
13.7.1	KEY PRODUCT LAUNCHES & REGULATORY APPROVALS	208
TABLE 160	KEY PRODUCT LAUNCHES & REGULATORY APPROVALS, 2020-2023	208
13.7.2	KEY DEALS	209
TABLE 161	KEY DEALS, 2020-2023	209
14	COMPANY PROFILES	210
14.1	KEY PLAYERS	210
	(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*	
14.1.1	F. HOFFMANN-LA ROCHE LTD.	210
TABLE 162	F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW	210
FIGURE 43	F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)	211
14.1.2	ABBOTT	217
TABLE 163	ABBOTT: COMPANY OVERVIEW	217
FIGURE 44	ABBOTT: COMPANY SNAPSHOT (2022)	218
14.1.3	BIOMERIEUX	224
TABLE 164	BIOMERIEUX: COMPANY OVERVIEW	224
FIGURE 45	BIOMERIEUX: COMPANY SNAPSHOT (2022)	225
14.1.4	SIEMENS HEALTHINEERS AG	231
TABLE 165	SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW	231
FIGURE 46	SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)	232
14.1.5	DANAHER	237
TABLE 166	DANAHER: COMPANY OVERVIEW	237
FIGURE 47	DANAHER: COMPANY SNAPSHOT (2022)	238
14.1.6	THERMO FISHER SCIENTIFIC INC.	243
TABLE 167	THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW	243
FIGURE 48	THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)	244
14.1.7	HOLOGIC, INC.	249
TABLE 168	HOLOGIC, INC.: COMPANY OVERVIEW	249
FIGURE 49	HOLOGIC, INC.: COMPANY SNAPSHOT (2022)	250
14.1.8	BECTON, DICKINSON AND COMPANY	254
TABLE 169	BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW	254
FIGURE 50	BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)	255
14.1.9	REVVITY	260
TABLE 170	REVVITY: COMPANY OVERVIEW	260
FIGURE 51	REVVITY: COMPANY SNAPSHOT (2022)	261
14.1.10	QIAGEN	266
TABLE 171	QIAGEN: COMPANY OVERVIEW	266
FIGURE 52	QIAGEN: COMPANY SNAPSHOT (2022)	267
14.1.11	SEEGENE INC.	270
TABLE 172	SEEGENE INC.: COMPANY OVERVIEW	270

FIGURE 53 SEEGENE INC.: COMPANY SNAPSHOT (2022) 271

14.2 OTHER PLAYERS 276

14.2.1 QUIDELORTHO CORPORATION 276

14.2.2 GRIFOLS, S.A. 279

14.2.3 DIASORIN S.P.A. 280

14.2.4 BIO-RAD LABORATORIES, INC. 282

14.2.5 SYSMEX CORPORATION 284

14.2.6 ORASURE TECHNOLOGIES 285

14.2.7 CO-DIAGNOSTICS, INC. 286

14.2.8 MERIDIAN BIOSCIENCE 287

14.2.9 CHEMBIO DIAGNOSTICS, INC. 289

14.2.10 TRINITY BIOTECH 290

14.2.11 GENETIC SIGNATURES LTD. 291

14.2.12 EPITOPE DIAGNOSTICS, INC. 292

14.2.13 TRIVITRON HEALTHCARE 294

14.2.14 ELITECH GROUP 295

14.2.15 MERIL LIFE SCIENCES PVT. LTD. 297

14.2.16 INBIOS INTERNATIONAL, INC. 298

14.2.17 UNIOGEN OY 299

14.2.18 VELA DIAGNOSTICS 300

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 APPENDIX 301

15.1 DISCUSSION GUIDE 301

15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 306

15.3 CUSTOMIZATION OPTIONS 308

15.4 RELATED REPORTS 308

15.5 AUTHOR DETAILS 309

Infectious Disease Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (Immunodiagnostics, NGS, PCR, ISH, INAAT), Disease (Hepatitis, HIV, HAI, HPV, Syphilis, TB, Flu) - Global Forecast to 2028

Market Report | 2024-01-09 | 303 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature